

A Novel Practice Guideline to Promote Access to Treatment for Opioid Use Disorder

Tyler J. Varisco, PharmD, PhD

Assistant Professor | Department of Pharmaceutical Health Outcomes and Policy


Assistant Director | Prescription Drug Misuse Education and Research Center

University of Houston College of Pharmacy



Office of the Provost
UNIVERSITY OF HOUSTON

The Need:



Medication Availability	Overall (n = 4984)	Chain (n = 3402)	Independent (n = 1582)
BUP/NX + NNS, n (%)	2054 (41.2)	1631 (47.9)	423 (26.7)
BUP/NX, n (%)	2406 (48.3)	1858 (54.6)	548 (34.6)
NNS, n (%)	3466 (69.5)	2699 (79.3)	767 (48.5)
BUP/NX Ordering Availability	Overall (n = 2578)	Chain (n = 1544)	Independent (n = 1034)
Willing to order, n (%)	1650 (64.0)	1159 (75.1)	491 (47.5)
Order time, mean (SD)	2.7 (2.2)	2.8 (2.2)	2.5 (2.2)
Order time, median (IQR)	2 (1–3)	2 (1–4)	2 (1–3)

1. Dowell D. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. *MMWR Recommendations and reports*. 2022;71
2. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ (Clinical research ed)*. 2010;341:c5475-c5475. doi:10.1136/bmj.c5475
3. Hill LG, Loera LJ, Torrez SB, et al. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. *Drug and alcohol dependence*. 2022/08/01/ 2022;237:109518. doi:https://doi.org/10.1016/j.drugalcdep.2022.109518

Why wouldn't pharmacies stock medication?

Stigma:

*"Nobody will sell insulin needles unless you have an injectable prescription at that pharmacy, and there's no law against it. The problem is that at the first pharmacy that does it, there will be people going to get needles and a girl will be ringing up all these people **you know** and so nobody wants that business. What would the community perception be?"*

Enforcement:


*"You know, **recently had a visit from the DEA** just a random inspection, and that [buprenorphine] was one of the key drugs they were interested in looking at"*

Wholesale Restrictions


*"If we dispense a hundred prescriptions, 20 of them can be controlled substances. **Once we hit that quota, game over.** You can order whatever you want. They won't ship anything."*

Perceived
Administrative
Risk

Clinical
Necessity



What we did about it:





Pharmacy Recommendations:

The Pharmacy Access to Resources and Medication for Opioid Use Disorder (PhARM-OD) Guideline outlines steps pharmacists can take to ease access to buprenorphine

- ✓ Maintain a sufficient supply of buprenorphine
- ✓ Recognize that opioid use disorder is a chronic disease with adverse outcomes that can be prevented by treatment
- ✓ Use prescription drug monitoring programs to supplement rather than substitute for clinical judgment when making dispensing decisions
- ✓ Don't assume that because a person had to travel to fill a prescription or is paying cash that the person is misusing or diverting buprenorphine
- ✓ Review telehealth prescriptions and prescriptions from in-person encounters with the same criteria
- ✓ Recognize reasons providers may elect to prescribe buprenorphine monotherapy
- ✓ Consider dispensing a minimal partial quantity of the prescription if there is a delay in communicating with prescribers
- ✓ Treat people living with OUD with empathy, compassion, and support



Dissemination and Next Steps:



Engaging Community Pharmacists in Improving Treatment Outcomes for Patients with Opioid Use Disorder

September 24, 2024

[PhARM-ODD Guideline](#)

[UH Grantee Page](#)

Today, the National Community Pharmacy Practice Group is part of an ambitious treatment for opioid use disorder. The group is designed to educate community pharmacists on buprenorphine clinical barriers to treatment. The assistant professor of the FORE-funded project hopes it will acculturate and educate

Activities:	Type
Harnessing the Evidence: Implementing NCPA and NABP's PhARM-ODD Guidelines to Improve Access to Buprenorphine in your Pharmacy	
Harnessing the Evidence: Implementing NCPA and NABP's PhARM-ODD Guidelines to Improve Access to Buprenorphine in your Pharmacy - Pre-Test	NCPA Pre-Test
Harnessing the Evidence: Implementing NCPA and NABP's PhARM-ODD Guidelines to Improve Access to Buprenorphine in your Pharmacy - Video	NCPA Video
Harnessing the Evidence: Implementing NCPA and NABP's PhARM-ODD Guidelines to Improve Access to Buprenorphine in your Pharmacy - Final Assessment	NCPA Post-Test



NCPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education of continuing pharmacy education credit.

Activities:	Type
Promoting the Ethical Care of Persons with Opioid Use Disorder: Considerations to maintain patient privacy and autonomy	
Promoting the Ethical Care of Persons with Opioid Use Disorder: Considerations to maintain patient privacy and autonomy - Pre-test	NCPA Pre-Test
Promoting the Ethical Care of Persons with Opioid Use Disorder: Considerations to maintain patient privacy and autonomy - Video	NCPA Video
Promoting the Ethical Care of Persons with Opioid Use Disorder: Considerations to maintain patient privacy and autonomy - Final Assessment	NCPA Post-Test



NCPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is eligible for continuing pharmacy education credit.

Thank you!



Prescription Drug
Misuse Education and
Research (PREMIER) Center

College of Pharmacy